Influence of solvents on the variety of crystalline forms of erythromycin

AAPS PharmSci

Volumn 5, Issue 2, 2003, Pages 39-47

  Mirza, Sabiruddin ^a   Miroshnyk, Inna ^a   Heinämäki, Jyrki ^a   Christiansen, Leena ^a   Karjalainen, Milja ^a   Yliruusi, Jouko ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Clathrate; Crystallization; Erythromycin; Isostructurality; Solvated crystals; X ray diffraction

Indexed keywords

2 BUTANONE; 2 PROPANOL; ACETONE; ALCOHOL; ERYTHROMYCIN; MACROLIDE; ORGANIC SOLVENT; VOLATILE ORGANIC COMPOUND; WATER;

ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; CRYSTALLIZATION; DIFFERENTIAL SCANNING CALORIMETRY; DRUG FORMULATION; DRUG STRUCTURE; MICROSCOPY; SOLVATION; STOICHIOMETRY; STRUCTURE ANALYSIS; TEMPERATURE DEPENDENCE; THERMOGRAVIMETRY; VIDEORECORDING; X RAY POWDER DIFFRACTION;

EID: 0346039315     PISSN: 15221060     EISSN: None     Source Type: Journal    
DOI: 10.1208/ps050212     Document Type: Article

References (15)

1. York P. Solid-state properties of powders in the formulation and processing of solid dosage forms. Int J Pharm. 1983;14:1-28.
2. Marshal PV, York P. Crystallization solvent induced solid-state and particulate modifications of nitrofurantoin. Int J Pharm. 1989;55:257-263.
3. Florence A, Attwood D. Physicochemical Principles of Pharmacy. 3rd ed. London, England: Macmillan Press Ltd. 1998:5-35.
4. Fukumori Y, Fukuda T, Yamamoto Y, et al. Physical characterization of erythromycin dihydrate, anhydrate and amorphous solid and their dissolution properties. Chem Pharm Bull. 1983;31:4029-4039.
5. Bauer J, Quick J, Oheim R. Alternate interpretation of the role of water in the erythromycin structure. J Pharm Sci. 1985;74:899-900.
6. Murthy KS, Turner NA, Nesbitt RU, Fawzi MB. Characterization of commercial lots of erythromycin base. Drug Dev Ind Pharm. 1986;12:665-690.
7. Laine E, Kahela P, Rajala R, Heikkilä T, Saarnivaara K, Piippo I. Crystal forms and bioavailability of erythromycin. Int J Pharm. 1987;38:33-38.
8. Stephenson GA, Stowell JG, Pascal HT, Pfeiffer RR, Byrn SR. Solid-state investigations of erythromycin A dihydrate: structure, NMR spectroscopy, and hygroscopicity. J Pharm Sci. 1997;86:1239-1244.
9. Bauer JF, Dziki W, Quick JE. Role of an isomorphic desolvate in dissolution failures of an erythromycin tablet formulation. J Pharm Sci. 1999;88:1222-1227.
10. Sarisuta N, Kumpugdee M, Müller BW, Puttipipatkhachorn S. Physico-chemical characterization of interactions between erythromycin and various film polymers. Int J Pharm. 1999;186:109-118.
11. Kawakami K, Numa T, Ida Y. Assessment of amorphous content by microcalorimetry. J Pharm Sci. 2002;91:417-423.
12. Kálmán A, Párkányi L. Isostructurality of organic compounds: a tool to estimate the complementarity of homo- and heteromolecular associates. In: Hargittai M, Hargittai I, eds. Advances in Molecular Structure Research. Vol. 3. Greenwich, CT: JAI Press; 1997:201-226.
13. Stephenson GA, Groleau EG, Kleemann RL, Xu W, Rigsbee DR. Formation of isomorphic desolvates: creating a molecular vacuum. J Pharm Sci. 1998;87:536-542.
14. Morris KR. Structural aspects of hydrates and solvates. In: Brittain HG, ed. Polymorphism in Pharmaceutical Solids. New York, NY: Marcel Dekker; 1999:125-181.
15. Byrn SR, Pfeiffer RR, Stowell JG. A Solid State Chemistry of Drugs. New York, NY: Academic Press; 1999:279-303.